Effects of (-)-OSU6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilization

Journal of Neural Transmission

Volumn 115, Issue 6, 2008, Pages 899-908

  Rung, Johan P ^a   Rung, Emilia ^a   Helgeson, Lisa ^a   Johansson, Anette M ^b   Svensson, Kjell ^b   Carlsson, Arvid ^a   Carlsson, Maria L ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

( ) 3 PPP; ( ) OSU6162; ACR16; Amisulpride; Aripiprazole; Dopaminergic stabilizers; Motor activity; Rat

Indexed keywords

3 [3 (METHYLSULFONYL)PHENYL] 1 PROPYLPIPERIDINE; AMISULPRIDE; APOMORPHINE; ARIPIPRAZOLE; HALOPERIDOL; PRECLAMOL; PROTEIN ACR 16; RECEPTOR PROTEIN;

ANIMAL BEHAVIOR; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG EFFECT; HABITUATION; IN VITRO STUDY; LOCOMOTION; MALE; MOTOR ACTIVITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; SIGNAL TRANSDUCTION;

ANIMALS; BRAIN; DOPAMINE; DOPAMINE AGENTS; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HABITUATION, PSYCHOPHYSIOLOGIC; MALE; MOTOR ACTIVITY; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; SYNAPTIC TRANSMISSION;

EID: 44949208426     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-008-0038-3     Document Type: Article

References (35)

1. Brandt-Christensen M, Andersen MB, Fink-Jensen A, Werge T, Gerlach J (2006) The substituted (S)-3-phenylpiperidine (-)-OSU6162 reduces apomorphine- and amphetamine-induced behaviour in Cebus apella monkeys. J Neural Transm 113(1):11-19
2. Buxton ILO (2005) Pharmacokinetics and pharmacodynamics: the dynamics of drug absorption, distribution, action, and elimination. In: Brunton LL, Lazo JS, Parker KL (eds) Goodman & Gilman's the pharmacological basis of therapeutics, 11th edn. McGraw-Hill, New York
3. Carlsson A (1983) Dopamine receptor agonists: intrinsic activity vs. state of receptor. J Neural Transm 57(4):309-315
4. Carlsson A (2001) A half-century of neurotransmitter research: impact on neurology and psychiatry (Nobel lecture). Chembiochem 2(7-8):484-493
5. Carlsson ML, Carlsson A, Nilsson M (2004) Schizophrenia: from dopamine to glutamate and back. Curr Med Chem 11(3):267-277
6. De Muth JE (1999) Basic statistics and pharmaceutical statistical applications, 1st edn. Marcel Dekker, New York
7. Gefvert O, Lindström LH, Dahlbäck O, Sonesson C, Waters N, Carlsson A, Tedroff J (2000) (-)-OSU6162 induces a rapid onset of antipsychotic effect after a single dose. A double-blind placebo-controlled pilot study. Scandinavian Society for Psychopharmacology, 41st annual meeting, Copenhagen, Denmark. Nord J Psychiat 54:93-94
8. Grubbs FE (1969) Procedures for detecting outlying observations in samples. Technometrics 11(1):1-21
9. Härtter S, Hüwel S, Lohmann T, Abou El Ela A, Langguth P, Hiemke C, Galla HJ (2003) How does the benzamide antipsychotic amisulpride get into the brain?-an in vitro approach comparing amisulpride with clozapine. Neuropsychopharmacology 28(11):1916-1922
10. Jordan S, Chen R, Johnson J, Regardie K, Tadori Y, Kikuchi T (2002a) Aripiprazole is a potent, partial agonist at cloned human D2L and native rat 5-HT1A receptors. Eur Neuropsychopharmacol 12(Suppl 3):293-294
11. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA (2002b) The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 441(3):137-140
12. Jordan S, Johnson JL, Regardie K, Chen R, Koprivica V, Tadori Y, Kambayashi J, Kitagawa H, Kikuchi T (2007a) Dopamine D2 receptor partial agonists display differential or contrasting characteristics in membrane and cell-based assays of dopamine D2 receptor signaling. Prog Neuropsychopharmacol Biol Psychiatry 31(2):348-356
13. Jordan S, Regardie K, Johnson JL, Chen R, Kambayashi J, McQuade R, Kitagawa H, Tadori Y, Kikuchi T (2007b) In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling. J Psychopharmacol 21(6):620-627
14. Lahti RA, Tamminga CA, Carlsson A (2007) Stimulating and inhibitory effects of the dopamine "stabilizer" (-)-OSU6162 on dopamine D(2) receptor function in vitro. J Neural Transm 114(9):1143-1146
15. Lundberg T, Tedroff J, Waters N, Sonesson C, Carlsson A, Hagström P, Lindström LH, Gefvert O (2002) Safety of early clinical experience with (-)-OSU6162, a dopaminergic stabilizer with antipsychotic properties. In: SCNP 43rd Annual and 2nd Mediterranean Meeting, Juan-les-Pins, France. Nord J Psychiatry 56:24
16. Malmberg Å, Mikaels Å, Mohell N (1998) Agonist and inverse agonist activity at the dopamine D3 receptor measured by guanosine 5'-[-Thio]triphosphate-[35S] binding. J Pharmacol Exp Ther 285(1):119-126
17. Natesan S, Svensson KA, Reckless GE, Nobrega JN, Barlow KB, Johansson AM, Kapur S (2006) The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1- propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl- piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat. J Pharmacol Exp Ther 318(2):810-818
18. Perrault G, Depoortere R, Morel E, Sanger DJ, Scatton B (1997) Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Exp Ther 280(1):73-82
19. Pontén H, Carlsson A, Kullingsjö J, Sonesson C, Waters ES, Waters N, Tedroff J (2002) The dopamine stabilizer ACR16 prevents L-DOPA induced sensitization in the 6-OHDA-lesioned rat. In: 32nd annual meeting, society for neuroscience, Orlando. Soc Neurosci Program No. 787.6
20. Rebec GV (1998) Real-time assessments of dopamine function during behavior: single-unit recording, iontophoresis, and fast-scan cyclic voltammetry in awake, unrestrained rats. Alcohol Clin Exp Res 22(1):32-40
21. Rung JP, Carlsson A, Rydén Markinhuhta K, Carlsson ML (2005a) The dopaminergic stabilizers (-)-OSU6162 and ACR16 reverse (+)-MK-801-induced social withdrawal in rats. Prog Neuropsychopharmacol Biol Psychiatry 29(5):833-839
22. Rung JP, Carlsson A, Rydén Markinhuhta K, Carlsson ML (2005b) (+)-MK-801 induced social withdrawal in rats; a model for negative symptoms of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 29(5):827-832
23. Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O, Oblin A, Gonon F, Carter C, Benavides J, Scatton B (1997) Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 280(1):83-97
24. Seeman P, Guan HC (2007) Dopamine partial agonist action of (-)OSU6162 is consistent with dopamine hyperactivity in psychosis. Eur J Pharmacol 557(2-3):151-153
25. Siegel S, Castellan NJ (1988) Nonparametric statistics for the behavioral sciences, 2nd edn. McGraw-Hill, New York, pp 206-216
26. Sokoloff P, Griffon N, Gullin O, Diaz J, Pilon C, Schwartz J-C (2003) The dopamine D3 receptor in the pathophysiology and treatment of neuropsychiatric disorders. In: Sidhu A, Laruelle M, Vernier P (eds) Dopamine receptors and transporters, 2nd edn. Marcel Dekker, New York
27. Sonesson C, Lin CH, Hansson L, Waters N, Svensson K, Carlsson A, Smith MW, Wikström H (1994) Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structure-activity relationships. J Med Chem 37(17):2735-2753
28. Ståhle L, Ungerstedt U (1986) Effects of neuroleptic drugs on the inhibition of exploratory behaviour induced by a low dose of apomorphine: implications for the identity of dopamine receptors. Pharmacol Biochem Behav 25(2):473-480
29. Svensson K, Johansson AM, Magnusson T, Carlsson A (1986) (+)-AJ 76 and (+)-UH 232: central stimulants acting as preferential dopamine autoreceptor antagonists. Naunyn Schmiedebergs Arch Pharmacol 334(3):234-245
30. Tadori Y, Miwa T, Tottori K, Burris KD, Stark A, Mori T, Kikuchi T (2005) Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic. Eur J Pharmacol 515(1-3):10-19
31. Tadori Y, Kitagawa H, Forbes RA, McQuade RD, Stark A, Kikuchi T (2007) Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912. Eur J Pharmacol 574(2-3):103-111
32. Tedroff J, Ekesbo A, Sonesson C, Waters N, Carlsson A (1999) Long-lasting improvement following (-)-OSU6162 in a patient with Huntington's disease. Neurology 53(7):1605-1606
33. Waters N, Svensson K, Haadsma Svensson SR, Smith MW, Carlsson A (1993) The dopamine D3-receptor: a postsynaptic receptor inhibitory on rat locomotor activity. J Neural Transm Gen Sect 94(1):11-19
34. Waters N, Löfberg L, Haadsma Svensson S, Svensson K, Sonesson C, Carlsson A (1994) Differential effects of dopamine D2 and D3 receptor antagonists in regard to dopamine release, in vivo receptor displacement and behaviour. J Neural Transm Gen Sect 98(1):39-55
35. Waters N, Carlsson A, Carlsson M, Martin P, Tedroff J, Kullingsjö J, Pettersson F, Sonesson C, Waters ES (2002) Pharmacology of ACR16, a dopamine stabilizer. In: 32nd annual meeting, society for neuroscience, Orlando. Soc Neurosci Program No. 894.13